Related Experiment Video
Updated: May 20, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial
Li-Li Gong1, Jian-Hao Peng, Fei-Fei Han
1Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, Beijing, China.
Introduction:
To investigate whether t-PA Alu repeat insertion/deletion (I/D) and PAI-1 4G/5G genetic variations are associated with the risk of MI.
Methods:
We conducted a meta-analysis to assess the association between the t-PA I/D and PAI-1 4G/5G polymorphisms and risk of MI. We also performed subgroup analyses based on ethnicity (Caucasian, Asian, and African), gender and age. Forty one eligible studies including 12,461 cases and 14,993 controls were identified to evaluate the impact of PAI-1 4G/5G polymorphism on MI. Seven studies investigated the relationship between t-PA I/D and MI.
Results:
This meta-analysis revealed that the PAI-1 4G allele (4G/4G and 4G/5G genotype) was associated with an increased risk of MI compared with the 5G allele in the overall population (OR=1.094, 95% CI=1.021 - 1.172, p=0.011). The relative risks of MI for 4G/4G genotype was increased when compared to 5G/5G genotype and 5G allele, with odds ratio at 1.157 (95% CI 1.015 - 1.320, p=0.029) and 1.126 (95% CI =1.015 - 1.249, p=0.025). However, the results show that the 4G/5G polymorphism risk for MI was not associated with ethnicity stratification as Caucasian, Asian or African population. No substantial differences in the genotype distributions were observed in the MI group and control group along the lines of gender and age. After multivariable analysis t-PA I/D polymorphism showed no consistent association with MI.
Conclusions:
This study suggests that the 4G/5G polymorphism of PAI-1 may be a risk factor for MI in overall populations.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Transient Ischemic Attack l: Introduction
Pharmacogenomics: Identification of New Drug Targets
Peripheral Artery Disease I: Introduction